Skip to content
DataLookout
Menu

PATCHNCT07920081

Psilocybin for Amblyopia - Targeting Critical Periods in Humans

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Change in Amblyopic Eye Visual Acuity
Timeframe: from Baseline to two weeks after experimental drug session 2
Change in Fellow Eye Visual Acuity
Timeframe: from Baseline to two weeks after experimental drug session 2

Secondary (5)

Challenging Experiences Questionnaire (CEQ)
11-Dimensional Altered States of Consciousness Questionnaire (11D-ASC)
The World Health Organization-Five Well-Being Index (WHO-5)
Amblyopia and Strabismus Questionnaire: English (ASQE)
Sheehan Disability Scale (SDS)

Arms and interventions

1 mg Psilocybin with Amblyopia TherapyExperimental
5 mg Psilocybin with Amblyopia TherapyExperimental
10 mg Psilocybin with Amblyopia TherapyExperimental
15 mg Psilocybin with Amblyopia TherapyExperimental
20 mg Psilocybin with Amblyopia TherapyExperimental
25 mg Psilocybin with Amblyopia TherapyExperimental

Behavioral: Amblyopia Therapy

Drugs: 1 mg Psilocybin, 5 mg Psilocybin, 10 mg Psilocybin, 15 mg Psilocybin, 20 mg Psilocybin, 25 mg Psilocybin

Sites

1 site in 1 country

  • Johns Hopkins Center for Psychedelic and Consciousness ResearchBaltimore, Maryland, United States